https://www.selleckchem.com/products/gdc-0068.html
8% (8/74). The overall pooled odds ratio was 1.51 (P=0.444). The incidence of secondary malignancy in the surgery and (neo-) adjuvant chemotherapy group was 7.6% (9/118) and that in the surgery alone group was 2.7% (2/74). The overall pooled odds ratio was 2.29 (P=0.187). Adjuvant chemotherapy did not appear to improve the prognosis of patients with periosteal osteosarcoma. No association was found between the use of adjuvant chemotherapy and development of secondary malignancies. Adjuvant chemotherapy did not appear to improve the pro
إعجاب
علق
شارك
